ommendations cannot be clear cut. It may be reasonable to offer antiviral therapy to patients with severe pain early on to ameliorate acute symptoms not controlled with analgesics, or to patients considered to be at higher risk of postherpetic neuralgia on the basis of age. Patients with ophthalmic zoster should receive treatment to reduce the risk of ocular complications. Patients with zoster in other dermatomes, or who are at low risk of postherpetic neuralgia because of younger age might justifiably be treated conservatively.

## References

- Jolleys JV. Treatment of shingles and post-herpetic neuralgia. BMJ 1989; 298: 1537-1538.
- Anonynmous. Acyclovir in general practice [editorial]. Drug Ther
- Bull 1992; 26: 101-103.

  Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 1957; 164: 256-269.

  Demoragas JM, Kierland RR. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193-196.
- Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; **25:** 571-575.
- Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; **61:** 310-316
- Schmader KE, Studenski S. Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the
- literature. J Gen Intern Med 1989; 4: 83-89. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl
- Lycka B. Postherpetic neuralgia and systemic corticosteroid therapy. Int J Dermatol 1990; 29: 523-527.
- Post BT, Philbrick JT. Do corticosteroids prevent postherpetic neuralgia? A review of the evidence. J Am Acad Dermatol 1988; 18:
- Mulrow CD. The medical review article: state of the science. Ann Intern Med 1987; 106: 485-488.
- Silagy CA. Developing a register of randomized controlled trials in primary care. *BMJ* 1993; **306:** 897-900.
- Chalmers I, Enkin M, Kerise MJNC (eds). Effective care in pregnancy and childbirth. Oxford University Press, 1988.
- Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977; 33: 159-174.
- Peto R. Why do we need systematic overviews of randomised trials? Stat Med 1987; 6: 233-240.
- Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomised trials. *Prog Cardiovasc Dis* 1985; **27:** 335-371.
- 17. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989; **8:** 141-151.
- McKendrick MW, Care C, Burke C, et al. Oral acyclovir in herpes zoster. J Antimicrob Chemother 1984; 15: 661-665.
- Cobo LM, Foulks GN, Leisegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986; 93: 763-770.
- Wassilew SW, Reimlinger S, Nasemann T, Jones D. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. Br J Dermatol 1987; **117:** 495-501.
- Huff JC, Bean B, Balfour HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85 suppl 2a: 84-89.
  Mandal BL, Dunbar EM, Ellis ME, et al. A double-masked, placebo-
- controlled trial of acyclovir cream in immunocompetent patients with herpes zoster. J Infect 1988; 17: 57-63.
- Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85 suppl
- Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-95. Harding SP, Porter SM. Oral acyclovir in herpes zoster
- ophthalmicus. Curr Eye Res 1991; 10 suppl: 177-182.
  Wood MJ, Johnson RW, McKendrick MW, et al. A randomised trial of acyclovir for 7 or 21 days with and without prednisolone for treatment of acute herpes zoster. *N Engl J Med* 1994; **330**: 896-900.
- Elliott FA. Treatment of herpes zoster with high doses of prednisone. Lancet 1964; 2: 610-611.

- 28. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; **211:** 1681-1683.
- Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia? *Br J Dermatol* 1980; **102:** 551-555.
- Clemmensen OJ, Andersen KE. ACTH versus placebo in herpes zoster treatment. Clin Exp Dermatol 1984; 9: 557-563.
- Esmann V, Geil JP, Kroon S, et al. Prednisolone does not prevent post-herpetic neuralgia. *Lancet* 1987; 2: 126-129. Juel-Jensen BE, MacCallum FO, MacKenzie AMR, Pike MC.
- Treatment of zoster with idoxuridine in dimethyl sulphoxide: results of two double-blind controlled trials. BMJ 1970; 4: 776-780. Wildenhoff KE, Ipsen J, Esmann V, et al. Treatment of zoster with
- idoxuridine ointment, including a multivariate analysis of symptoms and signs. Scand J Infect Dis 1979; 11: 1-9.
- Wildenhoff KE, Esmann V, Ipsen J. Treatment of trigeminal and thoracic zoster with idoxuridine. Sand J Infect Dis 1981; 13:
- Sklar SH, Blue WT, Alexander EF, Bodian CA. Herpes zoster: the treatment and prevention of neuralgia with adenosine monophosphate. JAMA 1985; 253: 1427-1430
- monophosphate. JAMA 1985; 253: 1427-1430.

  Payne CR, Menday P, Rogers T, Staughton R. Isoprinosine does not influence the natural history of herpes zoster or postherpetic neuralgia. Scand J Infect Dis 1989; 21: 15-18.

  Galbraith AW. Treatment of acute herpes zoster with amantadine hydrochloride (symmetrel). BMJ 1973; 4: 693-695.

  Galbraith AW. Prevention of acute post-herpetic neuralgia by amantidine hydrochloride. Br J Clin Pract 1983; Sept: 304-306.

  Kernbaum S, Hauchecorne J. Administration of levodopa for relief of herpes zoster pain. JAMA 1981; 246: 132-134.

  Levy DW, Banerjee AK, Glenny HP. Cimetidine in the treatment of herpes zoster. J R Coll Physicians (Lond) 1985; 19: 96-98.

  Brint-Nielsen P, Christiansen LV, Damsbo N, Norrelund N. Treatment of herpes zoster with cimetidine. Report of a double-blind

- Treatment of herpes zoster with cimetidine. Report of a double-blind investigation in general practice. Ugeskr Laeger 1987; 149: 2138-2139.
- Tyring S, Hahlike J, Cunningham A and the collaborative famciclovir herpes zoster study group. Efficacy and safety of famciclovir in the treatment of patients with herpes zoster: results of the first placebo controlled study. Abstract presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 1993.
- Aliaga A, Fernandez JM, Iglesias L, et al. A topical solution of 40% idoxuridine in dimethyl sulfoxide versus oral acyclovir in the treatment of herpes zoster. A multicentre double blind clinical study. Med Clin (Barc) 1992; 98: 245-249.
- Nye FJ. Efficacy and safety of famciclovir in the treatment of uncomplicated herpes zoster. Abstract presented at the 3rd Congress of the European Academy of Dermatology and Venereology,
- Copenhagen, Denmark, September 1993.
  Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating samples sizes for comparing independent proportions. Biometrics 1980; 36: 343-346.
- Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment [letter]. N Engl J Med 1988; 318: 1728.

## Acknowledgements

We thank Drs Iain Chalmers and Henry McQuay and two anonymous reviewers for their constructive comments on earlier drafts of the manuscript. The project was supported by grants from the scientific foundation board of the Royal College of General Practitioners and Oxford Regional Health Authority. T L is supported by the Imperial Cancer Research

## Address for correspondence

Dr T Lancaster, Department of Public Health and Primary Care, Gibson Building, Radcliffe Infirmary, Oxford OX2 6HE.

## Corrigendum - community pharmacy (letter)

In the letter by Steven Ford (Community pharmacy, Br J Gen Pract 1994; 44: 534-535) the reference to the quote in the second paragraph 'Pharmacy distribution of medicines costs up to 30-40% of the total medicines bill. Should the public really be paying this amount?' should have been to:

Brown P. Are pharmacists necessary? Scrip 1994; May: 3-4.